OncoCyte Corporation (0KCC.L)
0KCC.L Stock Price Chart
Explore OncoCyte Corporation interactive price chart. Choose custom timeframes to analyze 0KCC.L price movements and trends.
0KCC.L Company Profile
Discover essential business fundamentals and corporate details for OncoCyte Corporation (0KCC.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
46.00
Website
https://oncocyte.comCEO
Joshua Riggs
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
0KCC.L Financial Timeline
Browse a chronological timeline of OncoCyte Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 23 Mar 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $291.95K.
Earnings released on 12 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.24 by +20.73%, while revenue for the quarter reached $2.14M, beating expectations by +1.59K%.
Earnings released on 24 Mar 2025
EPS came in at -$1.93 falling short of the estimated -$0.40 by -381.98%, while revenue for the quarter reached $1.49M, beating expectations by +837.24%.
Earnings released on 12 Nov 2024
EPS came in at -$0.40 surpassing the estimated -$0.44 by +7.99%, while revenue for the quarter reached $115.00K, beating expectations by +13.11%.
Earnings released on 9 Aug 2024
EPS came in at -$0.35 surpassing the estimated -$0.56 by +37.15%, while revenue for the quarter reached $104.00K, missing expectations by -67.35%.
Earnings released on 16 May 2024
EPS came in at -$1.10 falling short of the estimated -$0.67 by -64.88%, while revenue for the quarter reached $176.00K, missing expectations by -49.71%.
Earnings released on 12 Apr 2024
EPS came in at -$2.09 falling short of the estimated -$0.70 by -198.60%, while revenue for the quarter reached $314.00K, beating expectations by +39.56%.
Earnings released on 9 Nov 2023
EPS came in at -$0.79 surpassing the estimated -$1.01 by +22.06%, while revenue for the quarter reached $429.00K, beating expectations by +37.28%.
Earnings released on 10 Aug 2023
EPS came in at -$20.60 falling short of the estimated -$1.30 by -1.49K%, while revenue for the quarter reached $463.00K, beating expectations by +27.72%.
Stock split effective on 25 Jul 2023
Shares were split 1:20, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at $0.44 surpassing the estimated -$1.80 by +124.48%, while revenue for the quarter reached $297.00K, missing expectations by -14.26%.
Earnings released on 29 Mar 2023
EPS came in at -$2.06, while revenue for the quarter reached $274.00K.
Earnings released on 30 Sept 2022
EPS came in at -$1.57 surpassing the estimated -$2.27 by +30.57%, while revenue for the quarter reached $1.02M, missing expectations by -31.50%.
Earnings released on 30 Jun 2022
EPS came in at -$1.47 surpassing the estimated -$2.40 by +38.81%, while revenue for the quarter reached $2.07M, missing expectations by -23.60%.
Earnings released on 31 Mar 2022
EPS came in at -$2.23 surpassing the estimated -$2.43 by +8.12%, while revenue for the quarter reached $1.42M, missing expectations by -36.48%.
Dividend declared on 15 Mar 2022
A dividend of $0.01 per share was announced, adjusted to $0.29.
Earnings released on 14 Mar 2022
EPS came in at -$7.78 falling short of the estimated -$2.46 by -216.76%, while revenue for the quarter reached $3.59M, beating expectations by +1.85%.
Earnings released on 9 Nov 2021
EPS came in at -$2.34 falling short of the estimated -$2.30 by -1.64%, while revenue for the quarter reached $2.03M, beating expectations by +15.78%.
Earnings released on 30 Sept 2021
EPS came in at -$3.02, while revenue for the quarter reached $984.00K.
Earnings released on 31 Mar 2021
EPS came in at -$0.95, while revenue for the quarter reached $1.12M.
Earnings released on 31 Dec 2020
EPS came in at -$1.87, while revenue for the quarter reached $503.00K.
Earnings released on 30 Sept 2020
EPS came in at -$2.02, while revenue for the quarter reached $555.00K.
0KCC.L Stock Performance
Access detailed 0KCC.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.